We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Increasing Leptin Hormone Reverses Type 2 Diabetes

By Biotechdaily staff writers
Posted on 28 Sep 2006
By employing a new gene therapy technique that increased the production of the appetite-controlling hormone leptin, researchers were able to reverse type 2 diabetes in mice, according to a new study published in the September 2006 online edition of Peptides.

A gene embedded in a harmless virus was injected into the brains of the mice to increase leptin production in the hypothalamus, which regulates this hormone. More...
Although past studies showed that leptin acts to regulate weight and appetite, this is the first time leptin has been shown to independently affect insulin secretion as well.

"We found that we were successful in keeping the blood levels of insulin low and at the same time keeping blood glucose levels at a normal range,” said senior author Satya Kalra, Ph.D., a professor of neuroscience at the University of Florida (Gainesville, USA). "In other words, we were able to correct diabetes in these animals under various challenges.”

Eating rich and fatty foods causes blood sugar levels to rise, which in turn causes the body to produce more insulin, a protein that helps the body use carbohydrates. Patients with type 2 diabetes often become resistant to the insulin they make, causing much of it to build up in the body. After gene therapy, tests revealed that the blood sugar and insulin levels in the mice that received the therapy had returned to normal, even when they were fed a high-fat diet. However, mice that ate a high-fat diet but did not receive gene therapy continued to overproduce insulin and have high blood sugar levels, which are markers for type 2 diabetes. In another arm of the current study, the researchers discovered that normal, nondiabetic rats that received leptin gene therapy also produced lower levels of insulin.

Apart from keeping blood sugar and insulin levels low, the gene therapy also enabled the rodents to live longer than other obese rodents. "Currently, we do not know if that is due to the correction of the diabetes or many of the diseases associated with diabetes,” said Dr. Kalra. "It is clinically known that diabetic patients have early onset mortality. If the diabetes is managed, there is an improvement in lifeplan.”



Related Links:
University of Florida

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
Chromogenic Culture System
InTray™ COLOREX™ ECC
Prefilled Tubes
Prefilled 5.0ml Tubes
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image Credit: iStock

Blood Test Measuring Tumor Proliferation May Guide Treatment Sequencing in Metastatic Melanoma

Metastatic melanoma remains difficult to manage because outcomes vary widely and early prognostic markers are limited. About half of patients carry a BRAF gene mutation, giving clinicians several first-line... Read more

Molecular Diagnostics

view channel
Image Credit: Adobe Stock

Comprehensive Genomic Testing Expands Treatment Options for Advanced Cancers

Selecting effective therapies for advanced cancers remains difficult because standard tumor testing often targets only a limited set of genes. As options dwindle, many patients face decisions without strong... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.